AEON Biopharma Inc. Class A Common Stock (AEON)

About AEON

AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of chronic and episodic migraine. It also develops ABP-450 for the treatment of gastroparesis and post-tra…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

8

Website

www.aeonbiopharma.com/

Fundamentals

1-day range

$0.2805$0.3147

Market cap

$14.41M

P/E (trailing)

—

P/E (forward)

-1.26

EPS (trailing)

$-4.16

Dividend yield

—

Beta

0.66

Avg. volume

2.60M

Forecasts

3 analyst ratings

AEON Biopharma Inc. Class A Common Stock Competitors

Chosen by industry and closest market cap.

• AEON

  AEON Biopharma Inc. Class A Common Stock

  $0.3095

  ▲ 5.27%
  Market cap $14.41MP/E —
  $0.1772$1.45
• PTN

  Palatin Technologies Inc. Common Stock

  $10.48

  ▼ 0.10%
  Market cap $14.64MP/E 85.09
  $5.61$31
• KTTA

  Pasithea Therapeutics Corp. Common Stock

  $0.5975

  ▲ 7.66%
  Market cap $14.92MP/E —
  $0.281$2.06
• CYCN

  Cyclerion Therapeutics Inc. Common Stock

  $3.81

  ▼ 4.51%
  Market cap $15.11MP/E —
  $1.03$8.48
• KALA

  KALA BIO Inc. Common Stock

  $0.6949

  ▼ 14.42%
  Market cap $15.14MP/E —
  $0.5867$1,030
• COCP

  Cocrystal Pharma Inc. Common Stock

  $1.11

  ▼ 2.63%
  Market cap $12.96MP/E —
  $0.76$2.67
• AKTX

  Akari Therapeutics plc ADS

  $11.03

  ▲ 22.42%
  Market cap $12.88MP/E Infinity
  $3.02$49.6

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• 12 Health Care Stocks Moving In Thursday's Intraday Session
  Benzinga · 8/27/2026
• AEON Biopharma Designates Paul Lee As Chief Regulatory Office
  Benzinga · 8/24/2026
• 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
  Benzinga · 8/19/2026
• AEON Biopharma Announces Final, Expanded Primary Structure Results And Preliminary Disulfide Bond Characterization Data Providing Complementary Evidence Supporting Molecular Similarity Of ABP-450 To BOTOX
  Benzinga · 8/19/2026
• 12 Health Care Stocks Moving In Friday's After-Market Session
  Benzinga · 8/14/2026
• HC Wainwright & Co. Maintains Buy on AEON Biopharma, Lowers Price Target to $1.2
  Benzinga · 8/14/2026
• AEON Biopharma Q2 EPS $(0.02) Beats $(0.12) Estimate
  Benzinga · 8/12/2026
• AEON Biopharma Regains NYSE American Compliance
  Benzinga · 8/3/2026

• Forth Marc · June 17, 2026 · Grant

  222.7K
• Carter Eric G · June 17, 2026 · Grant

  222.7K
• FISCHER JOST · June 17, 2026 · Grant

  222.7K
• Shelley B. Thunen · June 17, 2026 · Grant

  222.7K
• Robert J. Palmisano · June 17, 2026 · Grant

  222.7K
• Bencich John · April 2, 2026 · Grant

  754.7K
• Oh Chad · March 4, 2026 · Grant

  1.32M
• Wilson Alexander Blair · March 4, 2026 · Grant

  1.32M
• Sy Jennifer · March 4, 2026 · Grant

  925.9K

Institutional Ownership

March 31, 2026

Total shares held

2.83M

Total value held

$2.79M

Institutional holders

22